Effect of RAP-219 on Long Episodes and Clinical Seizures in Adults with Drug-Resistant Focal Seizures and an Implanted Responsive Neurostimulator (RNS) System by Baseline Long Episode and Clinical ...

BOSTON and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (Rapport or the Company), a clinical-stage biotechnology company dedicated to the discovery and ...

New analysis examines RAP-219’s effect during the first month of treatment and consistency of efficacy over the treatment period, effectiveness across baseline disease severities, and impact on ...

RAP-219 is a potential first-in-class, clinical-stage TARPγ8-specific AMPA receptor (AMPAR) negative allosteric modulator (NAM). Whereas AMPARs are distributed widely in the central nervous system, ...

New analysis examines RAP-219’s effect during the first month of treatment and consistency of efficacy over the treatment period, effectiveness across baseline disease severities, and impact on ...

Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures Rapport Therapeutics, Inc ...

Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire treatment period, along with consistent efficacy data regardless of patients’ ...